1100 Massachusetts Avenue
Floor 4
Cambridge, MA 02138
United States
617 453 1000
https://www.infi.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Ms. Adelene Q. Perkins | Chairman & CEO | 1.15M | N/A | 1960 |
Dr. Stephane Peluso Ph.D. | Chief Scientific Officer | 577.63k | N/A | 1970 |
Dr. Robert Ilaria Jr., M.D. | Chief Medical Officer | 643.54k | N/A | 1961 |
Dr. Lawrence E. Bloch J.D., M.D. | Pres & Treasurer | N/A | N/A | 1966 |
Ms. Melissa Hackel | VP of Fin. | N/A | N/A | N/A |
Dr. Jeffery L. Kutok M.D., Ph.D. | Chairman of Scientific Advisory Board | N/A | N/A | 1967 |
Mr. Seth A. Tasker J.D. | Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. | N/A | N/A | 1979 |
Jayne Kauffman | Sr. Exec. Coordinator | N/A | N/A | N/A |
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.